Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs propofol vs midazolam for early goal-directed sedation in septic shock
ChiCTR2300067651Phase 4Not yet recruiting
- Sponsor
- Department of Critical Care Medicine, Renmin Hospital of Wuhan University
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam, propofol and midazolam in septic shock (3 arms), sponsored by Department of Critical Care Medicine, Renmin Hospital of Wuhan University. Primary endpoint: RASS score. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
remimazolampropofolmidazolam
03
Conditions
septic shock
Beyond the preview
Go deeper on ChiCTR2300067651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067651.